|
|
|
|
IAS 18 |
|
IFRS 15 |
IFRS 15 |
IAS 18 |
IAS 18 |
IFRS 15 |
||
|
Consideration |
Consideration |
Collaboration start date |
Outstanding |
Deferred income reclassified from equity following adoption of IFRS 15 |
Outstanding |
Revenue |
Revenue |
Revenue |
Outstanding |
||
Agreement |
(thousand of $) |
(thousand of €) |
|
(thousand of €) |
||||||||
|
||||||||||||
Revenue recognition of considerations received prior to 31 December 2017 |
||||||||||||
Gilead collaboration agreement for filgotinib – Upfront payment |
300,000 |
275,558 |
January 2016 |
187,449 |
– |
187,449 |
84,806 |
84,806 |
62,488 |
102,643 |
||
Gilead collaboration agreement for filgotinib – Subscription agreement(1) |
N.A. |
39,003 |
January 2016 |
26,532 |
– |
26,532 |
12,004 |
12,004 |
8,845 |
14,528 |
||
Servier collaboration agreement for osteoarthritis – License fee |
N.A. |
6,000 |
June 2010 |
5,362 |
(5,362) |
– |
– |
1,532 |
638 |
– |
||
AbbVie collaboration agreement for CF – Upfront payment |
45,000 |
34,001 |
September 2013 |
– |
14,872 |
14,872 |
14,140 |
– |
– |
732 |
||
Total upfront payments and license fees: |
|
|
|
219,343 |
9,510 |
228,853 |
110,950 |
98,342 |
71,971 |
117,903 |
||
|
|
|
|
|
|
|
|
|
|
|
||
Gilead collaboration agreement for filgotinib – Milestone payments |
70,000 |
64,435 |
January 2016 |
– |
43,832 |
43,832 |
19,831 |
– |
9,354 |
24,001 |
||
AbbVie collaboration agreement for CF – Milestone payments |
77,500 |
68,310 |
September 2013 |
– |
29,878 |
29,878 |
28,406 |
– |
33,596 |
1,471 |
||
Total milestones: |
|
|
|
– |
73,710 |
73,710 |
48,237 |
– |
42,950 |
25,472 |
||
Total: |
|
|
|
219,343 |
83,220 |
302,563 |
159,187 |
98,342 |
114,921 |
143,375 |
||
Revenue recognition of considerations received in the year ended 31 December 2018 |
||||||||||||
Novartis collaboration agreement for MOR106 – Upfront payment |
N.A. |
47,500 |
September 2018 |
|
|
|
47,500 |
47,500 |
|
– |
||
AbbVie collaboration agreement for CF – Upfront payment |
45,000 |
38,874 |
September 2013 |
|
|
|
38,037 |
38,037 |
|
837 |
||
Total upfront payments and license fees: |
|
|
|
|
|
|
85,537 |
85,537 |
|
837 |
||
Gilead collaboration agreement for filgotinib – Milestone payments |
15,000 |
12,418 |
January 2016 |
|
|
|
7,793 |
12,418 |
|
4,625 |
||
AbbVie collaboration agreement for CF – Milestone payments |
10,000 |
8,548 |
September 2013 |
|
|
|
8,364 |
8,548 |
|
184 |
||
Servier collaboration agreement for osteoarthritis – Milestone payment |
N.A. |
9,000 |
June 2010 |
|
|
|
9,000 |
9,000 |
|
– |
||
Total milestones: |
|
|
|
|
|
|
25,157 |
29,966 |
|
4,809 |
||
Total: |
|
|
|
|
|
|
110,694 |
115,503 |
– |
5,646 |
||
Grand total: upfront payments and license fees and milestones |
269,881 |
213,845 |
|
149,021 |
||||||||